Design Therapeutics Inc. Common Stock (DSGN)
Stock · NASDAQ · Health Care
$10.33as of 10/16/2026
Price chart
Active signals
DSGN Signal Track Record
How signals performed across all stocks →What DSGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +1.3% | 58% | September 18, 2026 |
| Bollinger Band Breakout | 30 | +2.1% | 60% | June 17, 2026 |
| Bollinger Band Breakdown | 21 | +3.4% | 67% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -4.5% | 29% | October 6, 2026 |
| Any 20-session window (baseline) | +2.9% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DSGN
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifyin…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 55
- Website
- www.designtx.com/
Fundamentals
- 1-day range
- $9.81$10.61
- Market cap
- $861.75M
- P/E (trailing)
- —
- P/E (forward)
- -6.47
- EPS (trailing)
- $-1.18
- Dividend yield
- —
- Beta
- 1.72
- Avg. volume
- 603.5K
Forecasts
7 analyst ratings
Design Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- AMPHAmphastar Pharmaceuticals Inc. Common Stock$25.87▼ 2.08%Market cap $873.48MP/E 14.15$16.65$29.52
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- ANNXAnnexon Inc. Common Stock$3.41▼ 5.28%Market cap $917.52MP/E —$2.54$7.18
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| AMPH Amphastar Pharmaceuticals Inc. Common Stock | $873.48M | 14.15 | $25.87 | ▼ 2.08% | $16.65$29.52 |
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| ANNX Annexon Inc. Common Stock | $917.52M | — | $3.41 | ▼ 5.28% | $2.54$7.18 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027SeekingAlpha · 10/4/2026
- Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26benzinga · 10/2/2026
- Airbnb upgraded, Zscaler downgraded: Wall Street's top analyst callsYahoo · 10/2/2026
- Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26Benzinga · 10/2/2026
Insider Activity
Insider Actions →- Gover Justin D. · June 9, 2026 · Grant30.0K
- Berger Heather A. · June 9, 2026 · Grant30.0K
- George Simeon · June 9, 2026 · Grant30.0K
- LAPPE RODNEY W · June 9, 2026 · Grant30.0K
- Shapiro David · June 9, 2026 · Grant30.0K
- John P. Schmid · June 9, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 37.63M
- Total value held
- $391.38M
- Institutional holders
- 121
- Unknown6.53M
- Unknown2.97M
- Unknown2.72M
- Unknown2.59M
- Unknown2.13M
- Unknown1.95M
- Unknown1.74M
- Unknown1.61M
- Unknown1.53M
- Unknown1.35M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference
Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference. Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.